机构：[1]Department of Computer Science, Key Laboratory of Intelligent Manufacturing Technology of Ministry of Education, Shantou University, Shantou 515000, China.[2]Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou 510000, China.[3]Clinical Research Center, Hainan Provincial Hospital of Traditional Chinese Medicine, Haikou 570100, China.[4]Department of Clinical Laboratory, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.[5]Guangdong Institute of Microbiology, Guangdong Academy of Sciences, Guangzhou 510000, China.[6]Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Advances in immunotherapy have revolutionized treatments in many types of cancer. Traditional Chinese Medicine (TCM), which has a long history of clinical adjuvant application against cancer, is emerging as an important medical resource for developing innovative cancer treatments, including immunotherapy. In this study, we developed a quantitative and systems pharmacology-based framework to identify TCM-derived natural products for cancer immunotherapy. Specifically, we integrated 381 cancer immune response-related genes and a compound-target interaction network connecting 3273 proteins and 766 natural products from 66 cancer-related herbs based on literature-mining. Via systems pharmacology-based prediction, we uncovered 182 TCM-derived natural products having potential anti-tumor immune responses effect. Importantly, 32 of the 49 most promising natural products (success rate = 65.31%) are validated by multiple evidence, including published experimental data from clinical studies, in vitro and in vivo assays. We further identified the mechanism-of-action of TCM in cancer immunotherapy using network-based functional enrichment analysis. We showcased that three typical natural products (baicalin, wogonin, and oroxylin A) in Huangqin (Scutellaria baicalensis Georgi) potentially overcome resistance of known oncology agents by regulating tumor immunosuppressive microenvironments. In summary, this study offers a novel and effective systems pharmacology infrastructure for potential cancer immunotherapeutic development by exploiting the medical wealth of natural products in TCM.
基金：
This work was supported by the National Natural Science Foundation of China (No. 82074278, 81903912, and
81902693), Natural Science Foundation of Guangdong Province (2018A030310298), China Postdoctoral Science
Foundation funded project (2019M662878), and Key laboratory project of colleges and universities in Guangdong
province (No. 2019KSYS005).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2020]版：
大类|3 区综合性期刊
小类|3 区综合性期刊
最新[2025]版：
大类|3 区综合性期刊
小类|3 区综合性期刊
第一作者：
第一作者机构：[1]Department of Computer Science, Key Laboratory of Intelligent Manufacturing Technology of Ministry of Education, Shantou University, Shantou 515000, China.[2]Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou 510000, China.
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Chuipu Cai,Qihui Wu,Honghai Hong,et al.In silico identification of natural products from Traditional Chinese Medicine for cancer immunotherapy.[J].Scientific reports.2021,11(1):3332.doi:10.1038/s41598-021-82857-2.
APA：
Chuipu Cai,Qihui Wu,Honghai Hong,Liying He,Zhihong Liu...&Jiansong Fang.(2021).In silico identification of natural products from Traditional Chinese Medicine for cancer immunotherapy..Scientific reports,11,(1)
MLA：
Chuipu Cai,et al."In silico identification of natural products from Traditional Chinese Medicine for cancer immunotherapy.".Scientific reports 11..1(2021):3332
